John Gnann to Adult
This is a "connection" page, showing publications John Gnann has written about Adult.
Connection Strength
0.360
-
Lack of Efficacy of High-Titered Immunoglobulin in Patients with West Nile Virus Central Nervous System Disease. Emerg Infect Dis. 2019 11; 25(11):2064-2073.
Score: 0.048
-
CLINICAL PRACTICE. Genital Herpes. N Engl J Med. 2016 Aug 18; 375(7):666-74.
Score: 0.038
-
Impact of a rapid multiplex polymerase chain reaction blood culture identification technology on outcomes in patients with vancomycin-resistant Enterococcal bacteremia. Infect Dis (Lond). 2016 Oct; 48(10):732-7.
Score: 0.038
-
Herpes Simplex Encephalitis: Lack of Clinical Benefit of Long-term Valacyclovir Therapy. Clin Infect Dis. 2015 Sep 01; 61(5):683-91.
Score: 0.035
-
Reversible posterior leukoencephalopathy syndrome. Intern Emerg Med. 2014 Apr; 9(3):341-2.
Score: 0.031
-
Kaposi's varicelliform eruption. Intern Emerg Med. 2014 Feb; 9(1):101-2.
Score: 0.031
-
Mosquito bites and eastern equine encephalitis. QJM. 2014 May; 107(5):397-8.
Score: 0.031
-
A prospective study of genital herpes simplex virus type 2 infection in human immunodeficiency virus type 1 (HIV-1)-seropositive women: correlations with CD4 cell count and plasma HIV-1 RNA level. Clin Infect Dis. 2003 Jan 15; 36(2):207-11.
Score: 0.015
-
Viral encephalitis: familiar infections and emerging pathogens. Lancet. 2002 Feb 09; 359(9305):507-13.
Score: 0.014
-
Risk factors for mortality and progression to severe COVID-19 disease in the Southeast region in the United States: A report from the SEUS Study Group. Infect Control Hosp Epidemiol. 2021 12; 42(12):1464-1472.
Score: 0.013
-
Sorivudine versus acyclovir for treatment of dermatomal herpes zoster in human immunodeficiency virus-infected patients: results from a randomized, controlled clinical trial. Collaborative Antiviral Study Group/AIDS Clinical Trials Group, Herpes Zoster Study Group. Antimicrob Agents Chemother. 1998 May; 42(5):1139-45.
Score: 0.011
-
West Nile virus neuroinvasive disease: neurological manifestations and prospective longitudinal outcomes. BMC Infect Dis. 2014 May 09; 14:248.
Score: 0.008
-
Natural history and treatment of varicella-zoster in high-risk populations. J Hosp Infect. 1991 Jun; 18 Suppl A:317-29.
Score: 0.007
-
Herpes simplex encephalitis during treatment with tumor necrosis factor-alpha inhibitors. Clin Infect Dis. 2009 Sep 15; 49(6):924-7.
Score: 0.006
-
Famciclovir treatment options for patients with frequent outbreaks of recurrent genital herpes: the RELIEF trial. J Clin Virol. 2008 Oct; 43(2):190-5.
Score: 0.005
-
Randomized controlled multicenter trial of aerosolized ribavirin for respiratory syncytial virus upper respiratory tract infection in hematopoietic cell transplant recipients. Clin Infect Dis. 2007 Jan 15; 44(2):245-9.
Score: 0.005
-
A randomized, open-label study to evaluate the safety and pharmacokinetics of human hepatitis C immune globulin (Civacir) in liver transplant recipients. Liver Transpl. 2005 Aug; 11(8):941-9.
Score: 0.004
-
A phase II, double-masked, randomized, placebo-controlled evaluation of a human monoclonal anti-Cytomegalovirus antibody (MSL-109) in combination with standard therapy versus standard therapy alone in the treatment of AIDS patients with Cytomegalovirus retinitis. Antiviral Res. 2004 Nov; 64(2):103-11.
Score: 0.004
-
Safety and efficacy of nebulized zanamivir in hospitalized patients with serious influenza. Antivir Ther. 2003 Jun; 8(3):183-90.
Score: 0.004
-
Recurrence of the acute HIV syndrome after interruption of antiretroviral therapy in a patient with chronic HIV infection: A case report. Ann Intern Med. 2000 Sep 19; 133(6):435-8.
Score: 0.003
-
A mixed model for factors predictive of pain in AIDS patients with herpes zoster. J Pain Symptom Manage. 1999 Jun; 17(6):410-7.
Score: 0.003
-
Disseminated herpes zoster in the immunocompromised host: a comparative trial of acyclovir and vidarabine. The NIAID Collaborative Antiviral Study Group. J Infect Dis. 1992 Mar; 165(3):450-5.
Score: 0.002
-
Therapy for women hospitalized with acute pyelonephritis: a randomized trial of ampicillin versus trimethoprim-sulfamethoxazole for 14 days. J Infect Dis. 1991 Feb; 163(2):325-30.
Score: 0.002
-
Intravenous acyclovir therapy of first episodes of genital herpes: a multicenter double-blind, placebo-controlled trial. Am J Med. 1988 Sep; 85(3):301-6.
Score: 0.001
-
A collaborative study of patient-initiated treatment of recurrent genital herpes with topical acyclovir or placebo. J Infect Dis. 1984 Jul; 150(1):1-6.
Score: 0.001